Alkermes plc. Foreign Currency Transaction Gain (Loss), before Tax
Alkermes plc. (ALKS) reported Foreign Currency Transaction Gain (Loss), before Tax of $1.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossBeforeTax · last filed 2026-02-25
- Alkermes plc. foreign currency transaction gain (loss), before tax for fiscal 2025 was $1.00M.
- Alkermes plc. foreign currency transaction gain (loss), before tax for fiscal 2024 was -$800.00K.
- Alkermes plc. foreign currency transaction gain (loss), before tax for fiscal 2023 was -$500.00K, a 171.43% decline from fiscal 2022.
- Alkermes plc. foreign currency transaction gain (loss), before tax for fiscal 2022 was $700.00K.
| Period end | Foreign Currency Transaction Gain (Loss), before Tax 9 month | Foreign Currency Transaction Gain (Loss), before Tax 12 month |
|---|---|---|
| 2025-12-31 | $1.00M 10-K · filed 2026-02-25 | |
| 2024-12-31 | -$800.00K 10-K · filed 2026-02-25 | |
| 2023-12-31 | -$500.00K 10-K · filed 2026-02-25 | |
| 2022-12-31 | $700.00K 10-K · filed 2025-02-12 | |
| 2021-12-31 | -$300.00K 10-K · filed 2024-02-21 | |
| 2020-12-31 | $2.40M 10-K · filed 2023-02-16 | |
| 2019-12-31 | -$900.00K 10-K · filed 2022-02-16 | |
| 2018-12-31 | -$2.30M 10-K · filed 2021-02-11 | |
| 2017-12-31 | $3.70M 10-K · filed 2020-02-13 | |
| 2016-12-31 | $100.00K 10-K · filed 2019-02-15 | |
| 2015-12-31 | $1.40M 10-K · filed 2018-02-16 | |
| 2014-12-31 | $600.00K 10-K · filed 2017-02-17 | |
| 2013-12-31 | $200.00K 10-K · filed 2016-02-25 | |
| 2013-03-31 | $100.00K 10-K · filed 2015-02-24 | |
| 2012-03-31 | $500.00K 10-KT · filed 2014-02-27 | |
| 2011-03-31 | $0.00 10-K · filed 2013-05-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |